EBS Emergent Biosolutions Inc.

60.96
-1.19  -2%
Previous Close 62.15
Open 61.48
Price To Book 3.21
Market Cap 3105610614
Shares 50,945,056
Volume 412,515
Short Ratio 6.51
Av. Daily Volume 371,413

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 181231062
  2. 8-K/A [Amend] - Current report 181231057
  3. CT ORDER - Confidential treatment order 181201507
  4. CT ORDER - Confidential treatment order 181170182
  5. CT ORDER - Confidential treatment order 181170066

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced September 9, 2017. Completion due 2019.
FLU-IGIV
Influenza A
Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 2b data due mid-2019.
IONIS-FXIRx
End-stage renal disease
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
VLA1601
Zika vaccine
Phase 3 trial planned for 2019.
NuThrax
Anthrax vaccine

Latest News

  1. See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
  2. Read This Before Judging Emergent BioSolutions Inc’s (NYSE:EBS) ROE
  3. Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape
  4. Emergent Biosolutions (EBS) Up 14.1% Since Last Earnings Report: Can It Continue?
  5. Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint
  6. Emergent-Valneva Zika vaccine clears early trial
  7. Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
  8. EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS
  9. Edited Transcript of EBS earnings conference call or presentation 1-Nov-18 9:00pm GMT
  10. Emergent BioSolutions Nabs Its Acquisition (Times 2)
  11. Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
  12. Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates
  13. Emergent Biosolutions (EBS) Q3 Earnings and Revenues Lag Estimates
  14. Emergent Biosolutions: 3Q Earnings Snapshot
  15. European markets rise on hopes of a US-China trade agreement; banks in the spotlight
  16. Emergent BioSolutions Inc (EBS) Q3 2018 Earnings Conference Call Transcript
  17. Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018

SEC Filings

  1. 8-K/A [Amend] - Current report 181231062
  2. 8-K/A [Amend] - Current report 181231057
  3. CT ORDER - Confidential treatment order 181201507
  4. CT ORDER - Confidential treatment order 181170182
  5. CT ORDER - Confidential treatment order 181170066
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181155021
  7. 8-K - Current report 181154371
  8. D - Notice of Exempt Offering of Securities 181146761
  9. 8-K - Current report 181137785
  10. 8-K - Current report 181123088